Pharmaceutical company Lakes BioScience has secured planning consent for a £350m biomanufacturing plant in Cumbria, the UK.
To be located at Ulverston in Cumbria, the new plant will be constructed to produce modern medicines and boost the UK’s resilience.
Go deeper with GlobalData
The company is planning to build the new biomanufacturing plant on the disused land owned by GSK, the company that pledged to donate it to the community for economic development uses following its own plans to build a new pharmaceutical factory on the site in 2017 being shelved.
The planning consent for groundworks at the proposed facility follows GSK’s announcement to close its Ulverston factory.
Lakes BioScience’s proposal is expected to create nearly 250 jobs at an advanced factory, which will be producing monoclonal antibodies.
See Also:
Lakes BioScience director Pat McIver said: “Lakes BioScience will put the UK at the forefront of biopharma scientific research, development and manufacture, by building and operating a state-of-the art, fully digitised operation building on all the learning from the best practices around the world and putting it into one dynamic UK operation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData“We will build on a rich regional and national capability and create high-value jobs in Ulverston in a fast-growing sector to deliver life-changing and life-saving treatments.
“The global and national situation regarding the Covid-19 pandemic has shown the need is greater than ever for the manufacturing capability in the UK, which Lakes BioScience will deliver.
“For the UK to ensure its resilience in the supply of front line medicines now is the time to push forward and ensure that as a country we transition to new modern medicine manufacturing.”
———————————————————————————————————————
Artist’s impressions of Lakes BioScience’s biopharmaceuticals site in Ulverston, Cumbria. (Credit: Cision.)
